ARIDIS PHARMACEUTICALS INC (ARDS)       0.6885  +0.02 (+2.56%)

0.6885  +0.02 (+2.56%)

US0403341045 - Common Stock - After market: 0.6701 -0.02 (-2.67%)

ARIDIS PHARMACEUTICALS INC0.6885

NASDAQ:ARDS (2/3/2023, 7:25:26 PM)+0.02 (+2.56%)

After market: 0.6701 -0.02 (-2.67%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-21 2022-11-21/amc Earnings (Next) 03-29 2023-03-29/amc
Ins Owners 24.84% Inst Owners 9.51%
Market Cap 14.32M Shares 20.80M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 80
IPO 08-14 2018-08-14

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ARDS Daily chart

Company Profile

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. The company is headquartered in Los Gatos, California and currently employs 34 full-time employees. The company went IPO on 2018-08-14. The firm is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The firm's product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), cystic fibrosis and COVID-19. The firm's lead product candidate, AR-301, targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. Its clinical development activities are focused on AR-301, AR320, AR-701, and AR-501. Its MabIgX and lPEX discovery platforms enables the Company to rapidly screen, identify and optimize fully human therapeutic mAb product candidates directly from the B-cells of patients.

Company Info

ARIDIS PHARMACEUTICALS INC

983 University Avenue, Bldg. B

Los Gatos CALIFORNIA 95032

P: 14083851742.0

CEO: Vu Truong

Employees: 34

Website: https://aridispharma.com

ARDS News

News Image6 days ago - ChartmillWhich stocks have an unusual volume on Monday?

Let's have a look at the stocks with an unusual volume in today's session.

News Image9 days ago - ChartmillThese stocks have an unusual volume in today's session

Let's have a look at the stocks with an unusual volume in today's session.

News Image10 days ago - Seeking AlphaAridis stock slumps ~25% as antibody drug fails phase 3 trial in pneumonia

Aridis Pharmaceuticals (ARDS) monoclonal antibody therapy AR-301 failed the main goal in a phase 3 trial to treat Ventilator Associated Pneumonia ((VAP)) caused by Gram-positive...

News Image10 days ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off the day with an overview of the biggest pre-market stock movers that traders need to watch on Thursday!

News Image11 days ago - Aridis Pharmaceuticals, Inc.Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)

LOS GATOS, Calif, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002...

News Image11 days ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time to start off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday!

ARDS Twits

Here you can normally see the latest stock twits on ARDS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example